John B. Buse
University of North Carolina at Chapel Hill
Internal medicineEndocrinologySurgeryRandomized controlled trialIntensive care medicineHazard ratioPlaceboType 2 diabetesDiseaseInsulinGlycemicHypoglycemiaType 1 diabetesLiraglutideType 2 Diabetes MellitusIn patientFamily medicineClinical trialDiabetes mellitusMedicine
602Publications
118H-index
77.4kCitations
Publications 588
Newest
#1Piotr Witkowski (U of C: University of Chicago)H-Index: 28
#2Jon S. Odorico (UW: University of Wisconsin-Madison)H-Index: 53
Last. Wanxing Cui (Georgetown University)H-Index: 1
view all 0 authors...
The Food and Drug Administration (FDA) has been regulating human islets for allotransplantation as a biologic drug in the US. Consequently, the requirement of a biological license application (BLA) approval before clinical use of islet transplantation as a standard of care procedure has stalled the development of the field for the last 20 years. Herein, we provide our commentary to the multiple FDA’s position papers and guidance for industry arguing that BLA requirement has been inappropriately ...
Source
#1Anna R. Kahkoska (UNC: University of North Carolina at Chapel Hill)H-Index: 19
#2Trine Julie Abrahamsen (Novo Nordisk)H-Index: 7
Last. Richard A. Moffitt (SBU: Stony Brook University)H-Index: 21
view all 0 authors...
OBJECTIVE null To determine the respective associations of premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodium–glucose cotransporter 2 inhibitor (SGLT2i) use, compared with premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use, with severity of outcomes in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. null RESEARCH DESIGN AND METHODS null We analyzed observational data from SARS-CoV-2–positive adults in the National COVID Cohort Colla...
Source
#1Thomas W. MartensH-Index: 2
#2Roy W. BeckH-Index: 116
Last. Richard M. Bergenstal (HealthPartners)H-Index: 18
view all 24 authors...
Importance Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied. Objective To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. Design, Setting, and Participants This randomized clinical trial was conducted at 15 cen...
1 CitationsSource
#1Juan P. FriasH-Index: 26
Last. John B. BuseH-Index: 118
view all 0 authors...
Once-weekly (OW) subcutaneous semaglutide 0.5 and 1.0 mg are approved maintenance doses for type 2 diabetes (T2D) treatment. We hypothesized that a higher dose of 2.0 mg would provide additional glycemic control with more patients achieving treatment targets vs. 1.0 mg. null SUSTAIN FORTE (NCT03989232) was a randomized, double-blind, phase 3b trial investigating the efficacy and safety of OW semaglutide 2.0 vs. 1.0 mg after 40 weeks of treatment in 961 adults with T2D in need of treatment intens...
Source
Last. John B. BuseH-Index: 118
view all 0 authors...
Source
#1John B. BuseH-Index: 118
Last. Juan P. FriasH-Index: 26
view all 0 authors...
Source
#1Johannes F.E. Mann (FAU: University of Erlangen-Nuremberg)H-Index: 63
#2John B. Buse (UNC: University of North Carolina at Chapel Hill)H-Index: 118
Last. Vlado Perkovic (The George Institute for Global Health)H-Index: 93
view all 9 authors...
AIMS The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide appeared to reduce kidney outcomes (composite of macroalbuminuria, doubling of serum creatinine, renal-replacement therapy, or renal death) in patients with type 2 diabetes in the LEADER and SUSTAIN 6 trials, primarily driven by changes in albuminuria. We investigated whether effects on chronic kidney disease risk factors could explain this benefit. MATERIALS AND METHODS We evaluated the mediation effect o...
Source
#1Anastasia-Stefania Alexopoulos (Duke University)H-Index: 8
#2Andreas Andersen (Novo Nordisk)H-Index: 2
Last. John B. Buse (UNC: University of North Carolina at Chapel Hill)H-Index: 118
view all 5 authors...
In the DEVOTE and SWITCH 2 trials, insulin degludec 100 units/mL (degludec) was superior to insulin glargine 100 units/mL (glargine U100) with respect to the rates of severe (DEVOTE; across trial) and overall symptomatic (SWITCH 2; during maintenance period of the trial) hypoglycaemia in individuals with type 2 diabetes (T2D). In this post hoc analysis, data from 7635 individuals from DEVOTE and 720 individuals from SWITCH 2 were analyzed by subgroups of diabetes duration at baseline (<10, ≥10-<...
Source
#1Kalene Morozumi (UNC: University of North Carolina at Chapel Hill)
#2Tanha Patel (UNC: University of North Carolina at Chapel Hill)H-Index: 1
Last. Gaurav Dave (UNC: University of North Carolina at Chapel Hill)H-Index: 9
view all 9 authors...
Introduction Pilot programs are integral to catalyzing and accelerating research at Clinical and Translational Science Award (CTSA) hubs. However, little has been published about the structure and operationalization of pilot programs or how they impact the translational research enterprise at CTSAs. The North Carolina Translational and Clinical Science Institute (NC TraCS), the CTSA hub at the University of North Carolina at Chapel Hill (UNC-CH) conducted an evaluation case study to describe the...
Source
1 CitationsSource